Proactive Investors - Run By Investors For Investors

Allergy Therapeutics strengthens clinical research team with senior appointments

Pieter-Jan de Kam joins as clinical director, while Simon Piggott will become head of clinical science
picture of handshake
Allergy is strengthening its clnical research team

Allergy Therapeutics plc (LON:AGY) has strengthened its clinical research team with two senior appointments.

Pieter-Jan de Kam joins as clinical director, while Simon Piggott will become head of clinical science.

At his previous firm, Dutch firm HAL Allergy, de Kam was in charge of clinical development for pollen and dust mites, two key product development areas for Allergy.

Allergy Therapeutics revenues rise as hay fever portfolio cleans up

Piggot, meanwhile, has significant experience of taking respiratory development programs through Phase I to IV trials and will be responsible for the delivery of Allergy's clinical strategy and products pipeline.

In addition, Tim Higenbottam has been appointed to the position of senior pharmaceutical physician and will focus on the US regulatory process.

Murray Skinner, Allergy’s chief scientific officer of Allergy Therapeutics, said the trio’s vast experience and expert knowledge was ideal to help bring new and convenient into the allergy immunotherapy market."

View full AGY profile View Profile

Allergy Therapeutics plc Timeline

Related Articles

picture of doctor
September 06 2017
A Phase I clinical trial is to start later this year for the LOXL-2 inhibitor
picture of human skeleton
July 21 2017
Tissue Regenix is funding the acquisition with a placing at 10p to raise £40mln
July 27 2017
Regulatory sign-off will fire the starting pistol on the commercial launch in Europe

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use